Although left atrial appendage closure (LAAC) has proved non-inferior to oral anticoagulants in patients with AF, there has been recent concern about the occurrence of late complications, especially device-related thrombus (DRT), which was associated with increased risk of stroke. In this article, the incidence, risk factors and time course of DRT after LAAC are discussed, as well as the potential benefits of dedicated strategies in the management of DRT, which remain speculative, especially in patients with a contraindication to oral anticoagulants. In these patients, decision-making should be based on a multidisciplinary evaluation of the ischaemic/bleeding balance on an individual basis.
Left atrial appendage closure (LAAC) has been shown to be non-inferior to warfarin in decreasing the risk of stroke and systemic embolism in patients with AF. [1] [2] [3] In addition to peri-procedural complications (tamponade, device migration, procedure-related stroke or embolism, and vascular complications), there has been growing concern recently about the occurrence of late complications, especially device-related thrombus (DRT).
Although DRT has been previously reported in patients enrolled in Nevertheless, there is a probable causal relationship between DRT and stroke or systemic embolism, since a stroke has been reported to occur within 2 months of DRT detection in a non-negligible proportion of patients (nearly 50%) who had DRT and stroke.
Risk Factors for Device-Related Thrombus
There is clear evidence that the risk of DRT is not equal for all LAAC recipients. The risk of DRT is higher among those with larger left atrial appendages, a history of stroke or transient ischaemic attack, permanent AF, lower ejection fraction and vascular disease. 2 Interestingly, these conditions are associated with a higher risk of cardiac and arterial thrombosis, and some are components of the CHA 2 DS 2 -VASc score.
Some instances of DRT are also related to procedural characteristics, since the uncovered area of the left atrial appendage after deep implantation has been shown to be instrumental in thrombus formation. 6, 7 The question of whether DRT could be related to the post-procedural drug regimen is more controversial. On one hand, Device-Related Thrombus After LAAC Given that the time required for device sealing may vary depending on patients, devices and procedures, it is particularly difficult to design one method of imaging follow-up for all patients. US Food and Drug Administration-designed trials have proposed a 6-month follow-up TOE to potentially detect more DRTs but the ideal protocol has yet to be designed. Very late (>1 year post-procedure) DRT has not been assessed and is thought to be less frequent because of device sealing, which remains variable on an individual basis. However, in keeping with our observations regarding late coronary stent thrombosis, caution is warranted in the presence of stroke or systemic embolism >1 year after LAAC, and TOE should be repeated in these patients.
What We Do Not Know and What Is Speculated

Potential Unknown Risk Factors for Device-Related Thrombus
In addition to the patient-and procedural-level characteristics that have been reported as potential risk factors for DRT, certain general clinical conditions usually associated with thrombosis may well play a role in DRT, such as chronic renal failure, diabetes and hypercoagulability status. Inter-patient response variability to antiplatelet agents has been described after stent thrombosis. Although unproven in the setting of LAAC, it is probable that DRT is more likely to occur among poor responders to antiplatelet drugs.
Concern has been raised that certain design characteristics of the device may trigger the development of DRT, such as the protruding central screw being potentially associated with delayed sealing. In the absence of any comparison between the Watchman and Amplatzer™ devices, we cannot conclude whether either of these devices carry an adverse risk of DRT. However, companies have developed strategies to facilitate device sealing, which could result in a decreased rate of DRT.
Should We Manage Patients with a High Risk of Device-Related Thrombus Differently?
Whether patients at greater risk of DRT should be managed differently is questionable. Better screening and more aggressive drug regimens and DRT detection strategies are potentially beneficial in this subset of patients. DRT develops during the sealing process, before re-endothelialisation has been achieved. Oral anticoagulant and/or antiplatelet agents are given for several months to prevent thrombus formation.
We have learned from PROTECT AF and PREVAIL that TOE at 6 months resulted in the detection of more cases of DRT; however, no benefit was evidenced using this strategy in terms of stroke rate reduction in the whole population. [1] [2] [3] Case reports have shown DRTs resolving with adequate anticoagulation over several months, which should encourage increased surveillance after LAAC. 11, 12 Several options should be pointed out, such as postponing the 6-week follow-up TOE to 3-6 months post-procedure, or carrying out more aggressive TOE monitoring in patients at high risk of DRT; however, the latter exposes them to greater discomfort, as well as the risks inherent in additional transoesophageal examinations. In this setting, the benefit of using CT to detect a thrombus should be underlined because repeated TOE assessments are uncomfortable for patients and a potential source of complications.
One of the issues related to DRT is that reintroducing anticoagulants is associated with a high bleeding risk. Consequently, preventative and curative options are quite scarce in patients with a contraindication to oral anticoagulants. The answer to the question as to whether the contraindication is "relative" or "absolute" is obvious, and decision-making about DRT management should be based on a multidisciplinary evaluation of the ischaemia/bleeding balance on an individual basis.
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